Replimune Group (REPL)
Develops RPx oncolytic immunotherapies for melanoma and other solid tumors.
$13.47
After hours0.00 (0.00%)
At close$13.47(+4.66%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 101.98% | 96.09M shares | |
|---|---|---|---|
| 226 holders · as of Jun 30, 2026 | |||
| Insiders | 1.52% | 1.43M shares | |
| 5 holders · as of Aug 19, 2026 | |||
| Adds to | 103.50% | ||
94.22M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (94.22M in the company's Sep 22, 2026 report, 84.03M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 103.50%; nothing is left for Other.
13F, as of Jun 30, 2026
226 holders · 96.09M shares · 75 new positions · 149 increased · 45 reduced · 57 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 11.05M | 11.72% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 8.96M | 9.51% | +2.72M | Aug 7, 2026 |
| RTW Investments, LP | 7.41M | 7.87% | +54.7K | Aug 14, 2026 |
| Ridgeback Capital Investments L.P. | 7.31M | 7.76% | +7.31Mnew | Aug 14, 2026 |
| Goldman Sachs Group Inc | 4.54M | 4.82% | +2.26M | Aug 14, 2026 |
| State Street Corp | 4.44M | 4.71% | +657.9K | Aug 7, 2026 |
| Suvretta Capital Management, LLC | 4.39M | 4.66% | +168.0K | Aug 14, 2026 |
| Boxer Capital Management, LLC | 3.98M | 4.23% | +2.81M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors (GP) LLCincl. Felix J. Baker, Baker Bros. Advisors LP +1 more | 11.80% | 11.08M | 13D | Aug 11, 2026 |
| RTW Investments, LP | 8.90% | 7.36M | 13G | May 15, 2026 |
| Ridgeback Capital Investments L.P. | 7.60% | 6.25M | 13G | May 21, 2026 |
| The Goldman Sachs Group, Inc. | 5.30% | 4.42M | 13G | Aug 10, 2026 |
| State Street Corporation | 5.30% | 4.44M | 13G | Aug 7, 2026 |
| Suvretta Capital Management, LLC | 5.10% | 4.22M | 13G | May 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Emily Luisa Hillofficer: Chief Financial Officer | Sale | 9,256 | $14.28 | 215,852 |
| Aug 10, 2026 | Andrew Schwendenmanofficer: Chief Accounting Officer | Sale | 7,632 | $12.97 | 99,425 |
| Aug 10, 2026 | Konstantinos Xynosofficer: Chief Medical Officer | Sale | 11,447 | $12.97 | 224,215 |
| Aug 10, 2026 | Emily Luisa Hillofficer: Chief Financial Officer | Sale | 11,448 | $12.97 | 225,108 |
| Aug 10, 2026 | Sushil Pateldirector, officer: Chief Executive Officer | Sale | 39,341 | $12.97 | 708,151 |
| Aug 11, 2026 | Baker Bros. Advisors LPdirector, 10 percent owner: | Purchase · 2 lots | 2,736,340 | $0.0001 | 2,609,946 |
| Jun 1, 2026 | Christopher Sarchiofficer: Chief Commercial Officer | Sale | 12,000 | $9.24 | 180,962 |
| May 18, 2026 | Emily Luisa Hillofficer: Chief Financial Officer | Sale | 7,812 | $5.08 | 236,556 |
| May 18, 2026 | Sushil Pateldirector, officer: Chief Executive Officer | Sale | 37,324 | $5.08 | 747,492 |
| May 18, 2026 | Philip Astley-Sparkedirector | Sale | 17,657 | $5.08 | 1,412,414 |
House and Senate disclosures
Not reported.